Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.02.14	Actavis Confirms Generic Multaq Patent Challenge By Sanofi - Quick Facts (RTTNews)
24.02.14	Ardelyx Licenses NaP2b Phosphate Inhibitor Program To Sanofi (RTTNews)
18.02.14	Sanofi Announces European Commission Approval For NexGard - Quick Facts (RTTNews)
06.02.14	Sanofi Q4 Profit Surges On Lower Costs (RTTNews)
06.02.14	Sanofi Q4 Profit Rises - Quick Facts (RTTNews)
31.01.14	Lilly Issues Statement On Sanofi U.S. Lawsuit (RTTNews)
31.01.14	Sanofi Files Patent Infrigement Suit Agains Eli Lilly (RTTNews)
13.01.14	Genzyme Expands Alliance With Alnylam Pharma, To Invest $700 Mln For 12% Stake (RTTNews)
13.01.14	Alnylam Pharma, Genzyme Form New RNAi Therapeutics Alliance - Quick Facts (RTTNews)
30.12.13	Genzyme Gets Complete Response Letter From FDA On Lemtrada Application (RTTNews)
30.12.13	Genzyme Receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) Application (Businesswire)
19.12.13	Sanofi, Regeneron To Collaborate With ACC For PCSK9 Inhibitor Clinical Program (RTTNews)
13.12.13	Genzyme Says Health Canada Approves Lemtrada For Multiple Sclerosis (RTTNews)
12.12.13	Merial Granted EMA Approval For Broadline For Broad Spectrum Parasite Treatment (RTTNews)
03.12.13	Sanofi Reports Phase 3 Results For Investigational New Insulin U300 (RTTNews)
25.11.13	Alnylam Earns $7 Mln Milestone Payment From Genzyme On Patisiran Achievement (RTTNews)
24.11.13	Biogen Idec Gets Regulatory Protection For MS Drug Tecfidera In Europe (RTTNews)
22.11.13	Sanofi, Regeneron Report Positive Data With Sarilumab In Phase 3 Arthritis Trial (RTTNews)
22.11.13	Sanofi, Regeneron Report Positive Results With Sarilumab In First Phase 3 Trial (RTTNews)
18.11.13	Sanofi To Halt Clinical Trials Of JAK2 Inhibitor Fedratinib (RTTNews)
18.11.13	Sanofi Discontinues JAK2 Agent Fedratinib Clinical Trials - Quick Facts (RTTNews)
07.11.13	Sanofi Prices EUR 1 Bln Notes Due 2023 (RTTNews)
30.10.13	Sanofi Q3 Profit Down; Sees Annual EPS At Lower End Of Previous View (RTTNews)
30.10.13	Sanofi Q3 Profit Drops - Quick Facts (RTTNews)
22.10.13	Critical Alerts For Linn Energy, Texas Instruments, Clovis, Sanofi-Aventis, and Cliffs Natural Resources Released By InvestorsObserver (PR Newswire)
16.10.13	Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. (PR Newswire)
16.10.13	Sanofi, Regeneron Say Alirocumab Significantly Reduces Bad Cholesterol (RTTNews)
15.10.13	Nurses' association issues Open Letter to PM Stephen Harper and Premier Wynne urging both to act on poverty (PR Newswire)
07.10.13	Sanofi CEO Expects Return To Growth In Q4 : Bloomberg (RTTNews)
04.10.13	Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA (PR Newswire)
03.10.13	Genzyme Announces Positive Data From TOPIC Study Of Once-daily, Oral Aubagio (RTTNews)
01.10.13	Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly, Pfizer, Novartis, Sanofi, and AstraZeneca (PR Newswire)
26.09.13	Sanofi Announces the CE Mark for JuniorSTAR®, a New Half-Unit Insulin Reusable Pen for People with Type 1 Diabetes (PR Newswire)
25.09.13	Sanofi Announces Upcoming Launch of MyStar Extra®, the First Self-Monitoring Blood Glucose Meter With Estimated A1c (PR Newswire)
25.09.13	Drug Recommendations, Presentations, Marketing Authorizations, and Board Appointments - Research Report on Johnson & Johnson, Lilly, Sanofi, GSK, and Pacira (PR Newswire)
24.09.13	March of Dimes and Sanofi Pasteur Launch Sounds of Pertussis® "Grandparents' Corner" to Help Grandparents Better Protect Their Families from Whooping Cough (PR Newswire)
24.09.13	Data Show Sanofi's Lyxumia(R) Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled (PR Newswire)
24.09.13	Sanofi Reports GetGoal-L Sub-analysis Results - Quick Facts (RTTNews)
24.09.13	Sanofi Reports FDA Approval For NexGard Chewables - Quick Facts (RTTNews)
20.09.13	Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy Designation, Positive Results, and Drug Revival - Research Report on Johnson & Johnson, Lilly, GSK, Kythera, and Sanofi (PR Newswire)
19.09.13	Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine (PR Newswire)
18.09.13	Critical Alerts For Intel, Activision, Sanofi Aventis, AOL, and Las Vegas Sands Released By InvestorsObserver (PR Newswire)
17.09.13	Technical Study: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. (PR Newswire)
17.09.13	NDA Updates, Signed Agreements, Awarded Patents, and Clinical Study Results - Research Report on Merck, Bristol-Myers Squibb, Amarin, GlaxoSmithKline, and Sanofi (PR Newswire)
17.09.13	European Commission OKs Genzyme's Multiple Sclerosis Treatment Lemtrada (RTTNews)
16.09.13	Sanofi Re-Introduces Rolaids® in the United States (PR Newswire)
16.09.13	Sanofi Re-introduces Rolaids In U.S. - Quick Facts (RTTNews)
14.09.13	Sanofi Likely To Repurchase 9% Stake Of L'Oreal (RTTNews)
12.09.13	Sanofi To Withdraw Lixisenatide NDA In U.S. - Quick Facts (RTTNews)
10.09.13	FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals, and Prequalifications - Research Report on Johnson & Johnson, Novartis, AstraZeneca, Astex Pharmaceuticals, and Sanofi (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

20.12.24		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer
17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung

20.12.24

Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert